Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine

Drug Metabolism and Disposition

Volumn 40, Issue 2, 2012, Pages 276-282

  Shiraga, Toshifumi ^a   Yajima, Kanako ^b   Suzuki, Kenta ^b   Suzuki, Katsuhiro ^a   Hashimoto, Tadashi ^a   Iwatsubo, Takafumi ^a   Miyashita, Aiji ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DAREXABAN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9;

ARTICLE; CATALYSIS; CLEARANCE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG STRUCTURE; ENZYME SUBSTRATE; GENE EXPRESSION; HUMAN; INHIBITION KINETICS; INTESTINAL MICROSOME; INTESTINE; LIVER MICROSOME; MICROSOME; PRIORITY JOURNAL;

ANTICOAGULANTS; AZEPINES; BENZAMIDES; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; FACTOR XA; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; JEJUNUM; KINETICS; LIVER; MICROSOMES; MICROSOMES, LIVER; ORGAN SPECIFICITY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

BOVINAE;

EID: 84862907733     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042614     Document Type: Article

References (33)

1. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation - impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
2. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, and Obach RS (2008) Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260-2271.
3. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L, and ONYX-2 STUDY GROUP (2010) Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 8:714-721.
4. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566. (Pubitemid 30238515)
5. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297. (Pubitemid 33136266)
6. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354-363. (Pubitemid 39208734)
7. Groenendaal-van de Meent D, Heeringa M, Kadokura T, Verheggen F, Strabach G, and Heinzerling H (2010) YM150, an oral direct inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic/pharmacodynamic profile after single and multiple dosing: results from three studies (Abstract). Blood 116:3323.
8. Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, et al. (2011) Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido-)phenyl]-4-(4-methyl-1,4-diazepan-1-yl) benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem doi: 10.1021/jm200868m.
9. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254. (Pubitemid 30137047)
10. Itäaho K, Mackenzie PI, Ikushiro S, Miners JO, and Finel M (2008) The configuration of 17-hydroxy group variably influences the glucuronidation of β-estradiol and epiestradiol by human UDP-glucuronosyltransferase. Drug Metab Dispos 36:2307-2315.
11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, Suzuki M, Kawasaki T, Funatsu T, and Kaku S (2011) Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol doi:10.1016/j.ejphar.2011.10.009.
12. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T (2009) Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-1768.
13. Kaku S, Suzuki K, Funatsu T, Saitoh M, Koshio H, Ishihara T, Hirayama F, and Kawasaki T (2007) Effects of direct factor Xa inhibitor, YM150, on clot formation and clot lysis in vitro compared with other anticoagulants (Abstract). Blood 110:3153.
14. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132. (Pubitemid 40386722)
15. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
16. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
17. Milne RW, Nation RL, and Somogyi AA (1996) The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28:345-472. (Pubitemid 26300413)
18. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
19. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
20. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25. (Pubitemid 38268090)
21. Mulder GJ (1992) Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 32:25-49.
22. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
23. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
24. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
25. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
26. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
27. Saitoh M, Kaku S, Funatsu T, Koshio H, Ishihara T, Hirayama F, Kawasaki T, and Sasamata M (2007) Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models (Abstract). Blood 110:3155.
28. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
29. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
30. Turgeon D, Carrier JS, Lévesque E, Hum DW, and Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787. (Pubitemid 32222427)
31. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, and Davis HR Jr (2000) Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129:1748-1754. (Pubitemid 30219019)
32. Watanabe Y, Nakajima M, and Yokoi T (2002) Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469. (Pubitemid 35397055)
33. Yamanaka H, Nakajima M, Katoh M, and Yokoi T (2007) Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35:1642-1648. (Pubitemid 47296059)